Poster presentation at ESMO

RNS Number : 0424O

Diaceutics PLC

30 September 2019

 

Diaceutics PLC

("Diaceutics" or the "Company")

Poster presentation at ESMO

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will present a poster at the 2019 European Society of Medical Oncology Congress ("ESMO") in Barcelona today. ESMO will run from 27 September - 1 October 2019.

ESMO is the most influential oncology meeting in Europe, in partnership with the EACR (European Association for Cancer Research). The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care.

The Company will present a poster entitled "Known and unknown gene fusion detection capabilities of solid tumour laboratories conducting next generation sequencing in 6 countries". The Poster focusses on the current next generation sequencing ("NGS") capabilities in solid tumour oncology laboratories to detect unknown gene fusions, and concludes that labs in the EU have not kept up with the technical advances in NGS testing due to a lack of sufficient funding, which may lead to missed opportunities for improved treatment for patients.

The poster can be viewed via this link once it has been presented: 

http://www.rns-pdf.londonstockexchange.com/rns/0424O_1-2019-9-29.pdf

Enquiries:

Diaceutics PLC		www.diaceutics.com
Peter Keeling, Chief Executive Officer			via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)					[phone]
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy				Mob: [phone]
Paul McManus				Mob: [phone]

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

 

END

 

 

NRACKCDDKBKDPCB